MARKET

ZYME

ZYME

Zymeworks
NASDAQ
22.72
+0.70
+3.18%
After Hours: 22.60 -0.12 -0.53% 19:14 02/06 EST
OPEN
22.38
PREV CLOSE
22.02
HIGH
23.06
LOW
22.34
VOLUME
575.66K
TURNOVER
--
52 WEEK HIGH
28.49
52 WEEK LOW
9.03
MARKET CAP
1.70B
P/E (TTM)
-26.8939
1D
5D
1M
3M
1Y
5Y
1D
Zymeworks Inc. Files Initial Statement of Beneficial Ownership for SVP & Chief Medical Officer Sabeen Mekan
Reuters · 6d ago
Weekly Report: what happened at ZYME last week (0126-0130)?
Weekly Report · 6d ago
Zymeworks Inc. Joins Leerink Global Healthcare Conference for Fireside Chat
Reuters · 01/27 14:53
Zymeworks to Spotlight Pipeline and Portfolio at Series of Major Healthcare Investor Conferences
TipRanks · 01/27 11:38
Zymeworks Announces Participation in Upcoming Investor Conferences
Barchart · 01/27 05:00
Assessing Zymeworks (ZYME) Valuation After Major Leadership And Board Reshuffle
Simply Wall St · 01/26 19:21
Weekly Report: what happened at ZYME last week (0119-0123)?
Weekly Report · 01/26 10:12
Zymeworks Inc. unveils strategy focused on growing royalty portfolio and advancing novel medicines for difficult-to-treat diseases
Reuters · 01/20 17:29
More
About ZYME
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

Webull offers Zymeworks Inc stock information, including NASDAQ: ZYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYME stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZYME stock methods without spending real money on the virtual paper trading platform.